X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (582) 582
index medicus (559) 559
male (469) 469
middle aged (407) 407
aged (398) 398
oncology (373) 373
prognosis (346) 346
cancer-specific survival (321) 321
female (313) 313
urology & nephrology (292) 292
cancer (262) 262
survival (239) 239
cancer-specific mortality (221) 221
prostate cancer (213) 213
mortality (212) 212
adult (199) 199
retrospective studies (196) 196
surgery (192) 192
analysis (187) 187
neoplasm staging (165) 165
treatment outcome (160) 160
aged, 80 and over (158) 158
risk factors (151) 151
patient outcomes (147) 147
risk (143) 143
care and treatment (136) 136
survival rate (134) 134
urology (134) 134
radical prostatectomy (133) 133
metastasis (131) 131
proportional hazards models (124) 124
recurrence (124) 124
research (124) 124
carcinoma (115) 115
prostate-specific antigen - blood (108) 108
prostatic neoplasms - mortality (107) 107
prostatic neoplasms - surgery (104) 104
overall survival (103) 103
prostatic neoplasms - pathology (103) 103
disease-free survival (101) 101
kaplan-meier estimate (100) 100
survival analysis (99) 99
epidemiology (98) 98
health aspects (95) 95
follow-up studies (93) 93
multivariate analysis (92) 92
outcomes (87) 87
diagnosis (85) 85
impact (85) 85
kidney neoplasms - mortality (84) 84
prostatectomy (78) 78
men (76) 76
kidney neoplasms - pathology (75) 75
medicine & public health (75) 75
chemotherapy (73) 73
radiotherapy (73) 73
kidney neoplasms - surgery (72) 72
progression (72) 72
prostatic neoplasms - blood (71) 71
time factors (71) 71
biochemical recurrence (70) 70
carcinoma, renal cell - mortality (68) 68
medical prognosis (68) 68
risk assessment (68) 68
nephrectomy (67) 67
seer program (66) 66
age (65) 65
lymphatic metastasis (64) 64
tumors (64) 64
carcinoma, renal cell (63) 63
neoplasm grading (63) 63
oncology, experimental (63) 63
radiation-therapy (63) 63
renal cell carcinoma (63) 63
medical research (62) 62
nomogram (61) 61
breast cancer (59) 59
predictive value of tests (59) 59
therapy (59) 59
abridged index medicus (58) 58
cancer patients (58) 58
article (57) 57
cohort studies (57) 57
patients (57) 57
carcinoma, renal cell - surgery (56) 56
carcinoma, renal cell - pathology (55) 55
metastases (54) 54
young adult (53) 53
prostate (52) 52
prostate-specific antigen (52) 52
bladder cancer (51) 51
cancer‐specific survival (50) 50
disease progression (49) 49
cancer specific survival (48) 48
radical nephrectomy (48) 48
studies (48) 48
urothelial carcinoma (48) 48
development and progression (46) 46
hematology, oncology and palliative medicine (46) 46
medicine, experimental (46) 46
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 17, pp. 3326 - 3334
BACKGROUND Survival after the diagnosis of diffuse large B‐cell lymphoma (DLBCL) has been increasing since 2002 because of improved therapies; however,... 
causes of death | standardized mortality ratio | rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) | noncancer causes of death | cure | diffuse large B‐cell lymphoma | Surveillance, Epidemiology, and End Results (SEER) | cancer‐specific survival | cancer-specific survival | diffuse large B-cell lymphoma | rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) | UNITED-STATES | vincristine | EVENT-FREE SURVIVAL | PHASE-II | RISK | and End Results (SEER) | CHOP CHEMOTHERAPY | Epidemiology | CHEMOTHERAPY PLUS RITUXIMAB | rituximab with cyclophosphamide | TRIAL | THERAPY | Surveillance | ONCOLOGY | NON-HODGKIN-LYMPHOMA | doxorubicin | and prednisone (R-CHOP) | ELDERLY-PATIENTS | Predictive Value of Tests | Immunotherapy - methods | Age Factors | United States | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Cause of Death | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Retrospective Studies | Databases, Factual | SEER Program | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Proportional Hazards Models | Combined Modality Therapy | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Survival Analysis | Aged | Neoplasm Staging | Cancer patients | Chemotherapy | Usage | Lymphocytic leukemia | Diagnosis | Health aspects | Cancer | Cell survival | Gastrointestinal tract diseases | Risk groups | Mortality | Medical services | Patients | Survival | Lymphoma | Risk factors | Diseases | Extrapolation | Demographics | Vascular diseases | Lymphocytes B | Mathematical analysis | Risk assessment | Fatalities | Lymphomas | Health risk assessment | B-cell lymphoma
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 2015, Volume 42, Issue 3, pp. 419 - 425
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 707 - 710
Journal Article